Providing novel possibilities for all life.

↑ここにファーストビュー用のマスクあります↑

PLATFORM


Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost in a fraction of the time.
We aim to create state-of-the-art solutions to a myriad of problems surrounding pregnancy, including infertility as a result of age and hereditary disorders.

Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost in a fraction of the time.
We aim to create state-of-the-art solutions to a myriad of problems surrounding pregnancy, including infertility as a result of age and hereditary disorders.

↑ここにリードエリア用の白いマスクあります↑

Grow with Us

We’re looking for high-performing individuals who are passionate about science and excited to work in a collaborative environment fueled by a rigorous or entrepreneurial culture.

We’re looking for high-performing individuals who are passionate about science and excited to work in a collaborative environment fueled by a rigorous or entrepreneurial culture.

MEMBER

President and CEO

Kazuma Kishida

After graduating from Waseda University in 2020, engaged in the investment banking business at the US investment bank, Houlihan Lokey.
In 2021, he co-founded Dioseve Inc. and became CEO of the company.

Scientific Advisor

Nobuhiko Hamazaki Ph.D.

Worked as a researcher and associate professor at the Kyushu University School of Medicine from 2015 to 2020. Currently serving as HHMI Special Researcher at the University of Washington in the USA.
In 2021 he co-founded Dioseve Inc. and became the Chief Scientific Officer of the company.

Principal Scientist

Yasunari Seita Ph.D.

Obtained a Doctorate degree from Azabu University, and worked as a researcher at the Child Health Institute of New Jersey, Shiga University of Medical Science, and University of Pennsylvania.
Joined Dioseve in 2023

Senior Scientist

Kasane Kishi DVM, Ph.D.

Obtained a Doctorate degree from the Graduate School of Agricultural and Life Sciences, The University of Tokyo in 2018 and worked as a pharmacologist in Astellas Pharma Inc.
Joined Dioseve as Senior Scientist in 2023

Senior Scientist

Alexis Tam Ph.D.

Obtained Doctorate degree from the School of Biomedical Sciences, the University of Hong Kong in 2021 and continued to work as a post-doctoral fellow in Cheah’s Lab from the same school.
Joined Dioseve in 2022.

Senior Scientist

Kosei Ishiguro Ph.D.

Obtained a Doctorate degree from Tsukuba University, and worked as a researcher at the Veterinary Research Institute in Brno, Institute of Genetics and Molecular and Cellular Biology (IGBMC) in Strasbourg, and The Institute of Agrobiological Sciences, NARO (NIAS) in Tsukuba. Joined Dioseve in 2023.

Senior Scientist

Kaharul Kahar

Graduated from Universiti Kuala Lumpur Royal College of Medicine Perak in 2014 and engaged in research at Kyushu University’s Hayashi Laboratory.
Joined Dioseve as Senior Scientist in 2021.

Scientist

Kazuaki Kojima Ph.D.

Obtained a Doctorate degree from Yokohama City University, and worked as researcher at the National Center for Child Health and the Central Institute for Experimental Animals.
Joined Dioseve in 2022.

Scientist

Yuta Sato Ph.D.

Obtained a Doctorate degree from the Graduate School of Chemical Sciences and Engineering, Hokkaido University in 2019. Worked at Niigata University and Hokkaido University as a specially-appointed assistant professor.
Joined Dioseve in 2023.

Senior Research Associate

Maho Nishikawa Ph.D.

Obtained a Doctorate degree from the Graduate School of Tokyo University of Marine Science and Technology in 2019.
Worked at a company that provides cancer gene-related testing from 2019-2023.
Joined Dioseve in 2024.

Senior Research Associate

Etsuko Okada

Engaged in Sanwa Kagaku Kenkyusho as a Technician in 2013.
Academic Researcher at Kumamoto University in 2019.
Joined Dioseve in 2022.

Product Development Specialist

Takanori Saita

Graduated from Kyushu University and engaged in clinical development work at Mitsubishi Tanabe Pharma, as mainly development safety responsible person. After retirement, involved in the development of Muse cell. Joined Dioseve in 2024.

Corporate Associate

Keitaro Yamane Ph.D.

Obtained a Doctorate degree from the faculty of medicine, Osaka University in 2017 and worked at Edinburg University as a post-doctoral fellow. In 2020 engaged in Kobayashi Pharmaceutical Co., Ltd.
Joined Dioseve as Senior Scientist in 2022

External Advisor

Yoshinori Shinoki

Graduated from the Department of Biopharmaceuticals, Kyoto Pharmaceutical University.
Launched the Clinical Development Department at Eli Lilly Japan and Parexel International, and since 2015, General Manager of JConsulting Management Department.

External Advisor

Nobuhiko Suganuma M.D., Ph.D.

Professor Emeritus of Kyoto Univ. since 2018. Graduated from the Graduate School of Medicine, School of Medicine, Nagoya University. Director of Japan Society of Fertilization and Implantation. Director of Japan Society of Assisted Reproduction.
Board Chairman of Japan Society for Uterus Transplantation.

External Advisor

Nobuhiro Noro Ph.D.

Obtained the degree of Ph.D. at the Faculty of Science, Kyoto University, engaged in several research areas such as neurobiology and celular biology. Joined GlaxoSmithKline Co., Ltd. in 1997 and worked in drug discovery and late phase clinical development. Appointed as an corporate officer of the company in 2011. Appointed as the Chief Scientific Officer of Bonac Corporation in 2021, engaged in the research & development in nucleic acid medicine and corporate management.

INVESTORS

FEATURED IN

↑ここにアクセストップのマスクあります↑

ACCESS

Headquarters

1-17-8 Shinkiba, Koto-ku, Tokyo 136-0082, Japan Mitsui Link Lab Shinkiba 2 Room 223

Tokyo Office

6-10-1 Roppongi, Minato-ku, Tokyo 106-6115 Roppongi Hills Mori Tower 15F, CIRCLE by ANRI

Kumamoto Laboratory

2-2-1, Honjo, Chuo-ku, Kumamoto-shi, Kumamoto Kumamoto University, 860-8556